A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

This study is testing a combination of three drugs — tucidinostat (a type of epigenetic drug), sintilimab (an immunotherapy), and bevacizumab (an anti-blood vessel drug) — in people with advanced colorectal cancer that is not responding to standard treatments and has a specific genetic feature called MSS or pMMR. **You may be eligible if...** - You are between 18 and 75 years old with confirmed, inoperable, metastatic colorectal cancer - Your cancer has progressed despite prior treatment with standard chemotherapy drugs (fluoropyrimidine, irinotecan, oxaliplatin), with or without bevacizumab or cetuximab/panitumumab - Your tumor is confirmed MSS or pMMR (a genetic marker that usually means immunotherapy alone doesn't work well) - Your general health score and organ function are adequate **You may NOT be eligible if...** - You have not yet tried standard first-, second-, and third-line treatments - You have active autoimmune disease, uncontrolled infections, or serious heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.